| 000 | 01648 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250517145128.0 | ||
| 264 | 0 | _c20180528 | |
| 008 | 201805s 0 0 eng d | ||
| 022 | _a1477-0962 | ||
| 024 | 7 |
_a10.1177/0961203317700486 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBahloul, E | |
| 245 | 0 | 0 |
_aHydroxychloroquine-induced hyperpigmentation in systemic diseases: prevalence, clinical features and risk factors: a cross-sectional study of 41 cases. _h[electronic resource] |
| 260 |
_bLupus _cOct 2017 |
||
| 300 |
_a1304-1308 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAnticoagulants _xadministration & dosage |
| 650 | 0 | 4 |
_aAntimalarials _xadministration & dosage |
| 650 | 0 | 4 |
_aAntirheumatic Agents _xadministration & dosage |
| 650 | 0 | 4 | _aCross-Sectional Studies |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHydroxychloroquine _xadministration & dosage |
| 650 | 0 | 4 |
_aHyperpigmentation _xchemically induced |
| 650 | 0 | 4 |
_aLupus Erythematosus, Systemic _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPlatelet Aggregation Inhibitors _xadministration & dosage |
| 650 | 0 | 4 | _aPrevalence |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 | _aSurveys and Questionnaires |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aJallouli, M | |
| 700 | 1 | _aGarbaa, S | |
| 700 | 1 | _aMarzouk, S | |
| 700 | 1 | _aMasmoudi, A | |
| 700 | 1 | _aTurki, H | |
| 700 | 1 | _aBahloul, Z | |
| 773 | 0 |
_tLupus _gvol. 26 _gno. 12 _gp. 1304-1308 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1177/0961203317700486 _zAvailable from publisher's website |
| 999 |
_c27028751 _d27028751 |
||